It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SHTDY’s FA Score shows that 1 FA rating(s) are green whileZYXI’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SHTDY’s TA Score shows that 6 TA indicator(s) are bullish while ZYXI’s TA Score has 5 bullish TA indicator(s).
SHTDY (@Medical Distributors) experienced а -1.65% price change this week, while ZYXI (@Medical Distributors) price change was +4.57% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +1.56%. For the same industry, the average monthly price growth was +6.17%, and the average quarterly price growth was -12.83%.
ZYXI is expected to report earnings on Feb 27, 2025.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
SHTDY | ZYXI | SHTDY / ZYXI | |
Capitalization | 9.79B | 398M | 2,459% |
EBITDA | 26.2B | 17.9M | 146,369% |
Gain YTD | 6.568 | -18.457 | -36% |
P/E Ratio | 8.26 | 46.30 | 18% |
Revenue | 552B | 184M | 300,000% |
Total Cash | N/A | 44.6M | - |
Total Debt | N/A | 76.2M | - |
SHTDY | ZYXI | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 62 | |
PRICE GROWTH RATING 1..100 | 47 | 49 | |
P/E GROWTH RATING 1..100 | 65 | 9 | |
SEASONALITY SCORE 1..100 | 50 | 95 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SHTDY's Valuation (20) in the null industry is significantly better than the same rating for ZYXI (96) in the Medical Specialties industry. This means that SHTDY’s stock grew significantly faster than ZYXI’s over the last 12 months.
SHTDY's Profit vs Risk Rating (100) in the null industry is in the same range as ZYXI (100) in the Medical Specialties industry. This means that SHTDY’s stock grew similarly to ZYXI’s over the last 12 months.
ZYXI's SMR Rating (62) in the Medical Specialties industry is somewhat better than the same rating for SHTDY (100) in the null industry. This means that ZYXI’s stock grew somewhat faster than SHTDY’s over the last 12 months.
SHTDY's Price Growth Rating (47) in the null industry is in the same range as ZYXI (49) in the Medical Specialties industry. This means that SHTDY’s stock grew similarly to ZYXI’s over the last 12 months.
ZYXI's P/E Growth Rating (9) in the Medical Specialties industry is somewhat better than the same rating for SHTDY (65) in the null industry. This means that ZYXI’s stock grew somewhat faster than SHTDY’s over the last 12 months.
SHTDY | ZYXI | |
---|---|---|
RSI ODDS (%) | 2 days ago71% | 2 days ago65% |
Stochastic ODDS (%) | 2 days ago66% | 2 days ago76% |
Momentum ODDS (%) | 2 days ago62% | 2 days ago81% |
MACD ODDS (%) | 2 days ago74% | 2 days ago83% |
TrendWeek ODDS (%) | 2 days ago66% | 2 days ago82% |
TrendMonth ODDS (%) | 2 days ago66% | 2 days ago84% |
Advances ODDS (%) | 2 days ago70% | 5 days ago81% |
Declines ODDS (%) | 6 days ago69% | 14 days ago80% |
BollingerBands ODDS (%) | 2 days ago76% | 2 days ago78% |
Aroon ODDS (%) | 2 days ago61% | 2 days ago81% |
A.I.dvisor tells us that SHTDY and YI have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SHTDY and YI's prices will move in lockstep.
Ticker / NAME | Correlation To SHTDY | 1D Price Change % | ||
---|---|---|---|---|
SHTDY | 100% | +2.72% | ||
YI - SHTDY | 21% Poorly correlated | +3.56% | ||
SHTDF - SHTDY | 17% Poorly correlated | +32.74% | ||
HSIC - SHTDY | 11% Poorly correlated | +1.59% | ||
ZYXI - SHTDY | 9% Poorly correlated | -2.63% | ||
PDCO - SHTDY | 8% Poorly correlated | +2.48% | ||
More |
A.I.dvisor tells us that ZYXI and OMI have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZYXI and OMI's prices will move in lockstep.
Ticker / NAME | Correlation To ZYXI | 1D Price Change % | ||
---|---|---|---|---|
ZYXI | 100% | -2.63% | ||
OMI - ZYXI | 24% Poorly correlated | -0.75% | ||
HSIC - ZYXI | 17% Poorly correlated | +1.59% | ||
PDCO - ZYXI | 14% Poorly correlated | +2.48% | ||
COSM - ZYXI | 12% Poorly correlated | +1.25% | ||
GEG - ZYXI | 11% Poorly correlated | N/A | ||
More |